Halozyme Therapeutics Inc. Stock
Heavy losses for Halozyme Therapeutics Inc. today as the stock fell by -€6.980 (-10.270%).
With 21 Buy predictions and 2 Sell predictions Halozyme Therapeutics Inc. is one of the favorites of our community.
With a target price of 68 € there is a slightly positive potential of 9.43% for Halozyme Therapeutics Inc. compared to the current price of 62.14 €.
Our community identified positive and negative aspects for Halozyme Therapeutics Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Halozyme Therapeutics Inc. stock. On the other hand our users think that "Expected dividend yield" could be a problem in the future.
Pros and Cons of Halozyme Therapeutics Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
M***** P*******
Cons
?
B****
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Halozyme Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics Inc. | -10.270% | -7.254% | 1.205% | 12.126% | 6.041% | 34.721% | 56.091% |
| Iovance Biotherapeutics Inc. | 1.470% | 5.787% | 13.888% | -56.434% | -2.508% | -66.329% | -93.975% |
| United Therapeutics | 1.460% | 1.597% | 1.622% | 14.222% | -4.704% | 70.163% | 188.794% |
| Neurocrine Bioscience | -0.050% | -6.865% | -5.478% | -1.146% | -11.635% | 11.415% | 14.954% |
Comments
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at TD Cowen.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at Benchmark Co..
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Show more
Ratings data for HALO provided by MarketBeat
News
2 Under-the-Radar Biotech Stocks Set to Boom in 2026
The biotech sector returned to health in 2025 after years of sickly returns. A key sign of vitality was the SPDR S&P Biotech ETF (NASDAQ: IBB), which rose 27% in 2025, nearly doubling the 16% gain
Halozyme Therapeutics: A 6.3 Rating and a Future Full of Uncertainty
Explore the exciting world of Halozyme Therapeutics (NASDAQ: HALO) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights
The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar.
Over the last three months, the S&P 500 healthcare sector has risen 13%, compared to the broader S&P 500 index's 7% increase.
However, one stock that hasn't matched its sector's returns is Halozyme